Cellectis Exits Allogeneic CAR-T Development, Pivots to In Vivo Gene Editing for Severe Dyslipidemias
核心洞察
Cellectis' board approved a strategic transformation on September 11, 2026, ending internal development of CAR-T candidates lasme-cel (搜索) and eti-cel (搜索) and refocusing on in vivo gene editing.
The company will advance two preclinical programs, .HEAL-101 (搜索) targeting APOC3 for severe hypertriglyceridemia (搜索) and .HEAL-201 (搜索) targeting PCSK9 for severe hypercholesterolemia (搜索), both LNP-delivered.
Cellectis attributed the CAR-T exit to improved frontline regimens, bispecific antibody competition and slower enrollment, and will seek partners for the discontinued assets.
Cellectis will end internal development of its allogeneic CAR-T programs and reposition itself as an in vivo gene editing company, after its board of directors approved the strategic transformation on September 11, 2026. The Paris-based company will exit development of lasme-cel (搜索) and eti-cel (搜索) — its CAR-T candidates for B-cell acute lymphoblastic leukemia (搜索) (B-ALL) and non-Hodgkin lymphoma (搜索) (NHL), respectively — and concentrate resources on two preclinical programs in severe dyslipidemias. Cellectis said it will seek strategic partnering opportunities to maximize the value of the discontinued CAR-T assets.
The decision marks a sharp reversal for one of Europe's pioneers of off-the-shelf CAR-T. As recently as January, Cellectis described itself as a late-stage allogeneic CAR-T company and expected pivotal Phase 2 data from its lead program in 2026; about a month before the announcement, it reiterated plans for a Phase 2 interim analysis of lasme-cel (搜索) and full Phase 1 data for eti-cel (搜索) in the fourth quarter. The company is now replacing clinical-stage oncology assets with programs that have not yet entered human testing.
Landscape Shift, Not Clinical Failure
Cellectis framed the exit as a response to structural changes in the oncology landscape rather than to clinical failure. The company said continued and recently accelerated advances in frontline treatment regimens have lowered relapse rates, reducing the number of patients progressing to later lines of therapy where its allogeneic products were positioned. Concurrently, the rapid emergence of bispecific antibodies and in vivo CAR-T approaches has intensified competition in second- and third-line treatment settings.
"Together, these dynamics have reduced the addressable patient population for lasme-cel (搜索) and eti-cel (搜索), resulting in slower enrollment, a potentially longer and more costly development pathway, and therefore a delayed timeline to potential registration," the company stated. Cellectis added that it believes these trends are likely to continue and further constrain the commercial opportunity for both candidates.
The company said it retains conviction in the promise of allogeneic CAR T-cell therapies and cited strong physician interest in both assets, but concluded after a strategic review that the most effective use of its financial and operational resources is to accelerate its in vivo gene editing pipeline.
.HEAL-101: Base Editing of APOC3
The more advanced of the two new lead programs is .HEAL-101 (搜索), an in vivo base editing product candidate targeting the human APOC3 gene for severe hypertriglyceridemia (搜索) (sHTG). It uses a TALE-base editor specific to APOC3 ("APOC3 TALEB") formulated in lipid nanoparticles (LNP) and delivered intravenously.
Cellectis describes sHTG as a significant unmet medical need, with affected patients facing a high risk of acute pancreatitis, an increased burden of cardiovascular disease and limited treatment options. The program is being developed for high-risk patients, including those with triglyceride levels ≥880 mg/dL or ≥500 mg/dL with a history of acute pancreatitis — an estimated target population of approximately 1 to 2 million patients across the United States and Europe.
In preclinical work, the APOC3 TALEB displayed high on-site base editing activity when transfected as mRNA in a hepatic cell line (mean base editing >70%), and editing translated into a deep reduction of APOC3 protein secretion (mean reduction >70%). The candidate showed a highly specific base editing profile using an unbiased, genome-wide off-site identification method.
In a liver-humanized normolipidemic murine model, intravenous .HEAL-101 (搜索) edited human APOC3 (mean on-site base editing ~55%) and decreased plasma APOC3 levels (mean decrease ~60%; up to 70%), associated with a reduction in circulating triglycerides (mean decrease ~45%; up to 68% versus pre-treatment baseline). The company reported no significant increase in liver alanine aminotransferase (ALT) compared with untreated controls. In a hypertriglyceridemic humanized APOC3 transgenic murine model, .HEAL-101 significantly decreased plasma APOC3 levels (mean decrease ~70%) and triglyceride levels (mean decrease ~76%) versus pre-treatment baseline.
Cellectis plans to initiate a Phase 1 investigator-initiated trial (IIT) in China and report preliminary clinical data in H2 2027.
.HEAL-201: Epigenetic Silencing of PCSK9
The second program, .HEAL-201 (搜索), is an in vivo epigenetic editing candidate targeting the human PCSK9 gene for severe hypercholesterolemia (搜索). It employs a TALE-epigenetic modulator specific to the PCSK9 promoter ("PCSK9 TALEM") formulated in LNP.
Cellectis notes that severe hypercholesterolemia (搜索) remains a major driver of atherosclerotic cardiovascular disease, with many high-risk patients continuing to have elevated LDL cholesterol despite currently available therapies. The burden is particularly significant among younger high-risk patients with severe genetic forms of hypercholesterolemia and those with premature cardiovascular disease, representing an estimated 1 to 2 million patients across the United States and Europe.
The PCSK9 TALEM demonstrated high on-site epigenome editing activity when transfected as mRNA in a hepatic cell line (mean editing >90%), translating into a stable, deep and significant reduction of PCSK9 transcript levels and PCSK9 secretion without evidence of off-site gene and protein modulation. Intravenous administration of PCSK9 TALEM mRNA LNPs in a liver-humanized murine model decreased plasma PCSK9 levels by a mean of more than 90%.
A Phase 1 IIT in China is planned, with preliminary clinical data expected in H1 2028. Both programs are designed to alter gene activity without creating double-strand DNA breaks.
Platform Breadth and a Competitive Field
Cellectis said its core competencies span nuclease editing, base editing, epigenetic editing and transcriptional regulation. While most gene editing companies focus on a single editing modality, the company said its toolbox — built over a quarter century — allows it to combine therapeutic targets with several editing modalities.
"Gene surgery has the potential to transform the treatment of high-risk metabolic diseases by delivering long-lasting benefits through a single IV injection," said André Choulika, Ph.D., Co-Founder and Chief Executive Officer of Cellectis. "Our decision to focus Cellectis on in vivo Gene Editing reflects the progress we have made with .HEAL-101 (搜索) and .HEAL-201 (搜索) and our assessment of where our gene editing capabilities can be most effectively deployed."
Cellectis is entering an increasingly active field of liver-directed gene editing for cardiovascular and metabolic disease. Eli Lilly, through its 2025 acquisition of Verve Therapeutics, is developing in vivo editing programs targeting PCSK9 and ANGPTL3 (搜索); Verve reported Phase 1 data this year showing its PCSK9 base editor VERVE-102 reduced LDL cholesterol by as much as 62% after a single infusion and plans to move into Phase 2. CRISPR Therapeutics has already reported Phase 1 human data for its ANGPTL3-directed CTX310. Cellectis' use of TALE-based base and epigenetic editors differentiates its technical approach from these CRISPR-derived systems, though neither .HEAL program has yet generated human clinical data.
Financial and Operational Realignment
Cellectis will realign its organization and resources around the in vivo pipeline while maintaining its existing cell therapy partnerships with AstraZeneca, Allogene Therapeutics, Servier and Iovance Biotherapeutics. The restructuring — subject to works council consultation under applicable French labor law and US labor law requirements — is designed to extend the company's cash runway from a previously projected Q4 2027 into H2 2028, excluding any impact from potential future partnering of lasme-cel (搜索) or eti-cel (搜索). The company said the extension provides financial flexibility to advance the in vivo pipeline through key development milestones.
Investors reacted negatively: Cellectis shares fell as much as 43% in Monday trading following the announcement, trading at around $2 apiece, just above all-time lows. Trading of the company's ordinary shares on the Euronext Growth market of Euronext Paris was temporarily halted at the company's request on Monday, September 14, 2026, from the market open at 9:00 a.m. CET until the opening of the Nasdaq Global Market at 3:30 p.m. CET. Cellectis management hosted a conference call and webcast on September 14, in English at 8:00 a.m. ET and in French at 9:00 a.m. ET.
The strategy shifts development emphasis toward assets that remain preclinical, and Cellectis acknowledged in its forward-looking disclosures that preclinical animal model data may not translate into further preclinical development or the clinical setting, and that promising preclinical data may not yield positive clinical results. The next major evidence for the new direction will come from whether the preclinical editing and biomarker effects translate into initial human results, beginning with the .HEAL-101 (搜索) Phase 1 IIT in China.